Looking at the long-term horizon, the innovative medicines and vaccines of tomorrow will likely come from a broad spectrum of sources and geographies, enabled by collaborations, alliances and partnerships. No one entity working in isolation will be sufficient to achieve the healthcare innovation of the future.
Biopharmaceutical companies are working to expand opportunities to partner with the public sector through efforts like FDA’s Critical Path Initiative (which calls for collaboration between regulators, biopharmaceutical companies and academia to advance the methods and processes employed in clinical trials) and the National Institute of Health’s Roadmap for Medical Research (which calls for overcoming specific hurdles and filling defined knowledge gaps to address roadblocks to biomedical research). Positive outcomes from these partnerships may result in more fruitful discovery efforts and could improve the economics of drug development.
Improving R&D return is a priority for the entire industry to sustain an innovative biopharmaceutical R&D model. To deliver this, industry/ academic collaborations will be key. Pfizer is addressing today’s R&D productivity challenges by moving on two fronts to access the best science and rapidly translate it into new medicines. We are: 1) focusing our research hubs in major centers of biomedical innovation; and 2) expanding Centers for Therapeutic Innovation (CTI) – a new collaboration model of global partnerships between Academic Medical Centers and Pfizer to accelerate research and development to deliver unparalleled innovation, the best internal and external science, and industry leading productivity within a vibrant, diverse culture.
Beyond academic collaborations, our industry must define new and different ways to partner with world health organizations, patient organizations, governments and payers to increase the likelihood of success in developing differentiated and valuable new therapeutic options. It is through these new and expansive approaches to external strategic collaborations that the industry will see improved speed of new medicine development.
This will require changes in mindset and behavior across the healthcare ecosystem and demand greater openness and transparency. The world of healthcare has seen remarkable advances in our lifetime. We will need to construct new and more integrated models if we are to deliver continued innovation and progress to meet medical need.Dr. Yvonne Greenstreet, MD has been Senior Vice President and Head of Medicines Development for the Specialty Care Business Unit at Pfizer Inc. since February 1, 2011. Dr. Greenstreet serves as a Senior Vice President and Chief of Strategy, R&D at GlaxoSmithKline. At GlaxoSmithKline, she is responsible for leading strategy development and driving the transformation of Research and Development to address evolving healthcare needs. She is also a member of the GlaxoSmithKline’s Global Product Management Board. Dr. Greenstreet has more than 16 years of Pharmaceutical Industry experience in medicines development, medical affairs and business development. She served as Senior Vice President and Head of the Musculoskeletal, Inflammation Gastrointestinal & Urogenital Medicine Development Centre at GlaxoSmithKline (GSK) where she defined pipeline strategy and built a promising portfolio, successfully inlicensing several clinical stage assets as well as bringing three new significant medicines to market. Previously, Dr. Greenstreet served as Vice President and Head of European Clinical Development and Medical Affairs, and as Chief Medical Officer of GSK in Europe, where she was responsible for the development and delivery of European phase II-IV clinical plans, studies and submissions. She also served as Vice President and Medical Director for Pharmaceutical business in the UK, where she also served on the Advisory Committee for Topic Selection for NICE, the Association of the British Pharmaceutical Industry Medical Committee and the Prescription Medicines Code of Practice Authority Appeal Board. She served as an Independent Director of Molecular Insight Pharmaceuticals, Inc. from September 2008 to January 2010. Dr. Greenstreet graduated in medicine from the University of Leeds, and studied at several London teaching hospitals including St. Thomas’, St. Mary’s University College and St. Bartholomew’s. She obtained an M.B.A from INSEAD, France.